Carazolol, a compound identified by CAS number 57775-29-8, holds significant importance in the field of pharmaceutical research due to its potent activity as a beta-adrenergic receptor (beta-AR) antagonist. This article delves into the detailed chemical profile of Carazolol, encompassing its molecular structure, physical properties, and its pharmacological relevance, particularly in cardiovascular applications.

The chemical identity of Carazolol is precisely defined by its molecular formula, C18H22N2O2, and a molecular weight of 298.38 g/mol. The compound's structure features a carbazole moiety linked via an ether bridge to a propanolamine chain, with an isopropyl group attached to the nitrogen atom. Typically appearing as a yellowish solid, Carazolol's precise three-dimensional structure and stereochemistry are crucial for its biological activity. Researchers often seek to buy Carazolol that meets stringent purity standards, usually above 98%, to ensure reliable experimental results.

As a beta-adrenergic receptor antagonist, Carazolol exhibits high affinity for human beta1-, beta2-, and beta3-ARs. Its pharmacological action includes reducing epinephrine-induced increases in mean arterial blood pressure and heart rate. This characteristic makes Carazolol a valuable subject of study for understanding the mechanisms of hypertension and developing novel antihypertensive drugs. The availability of Carazolol from reputable manufacturers, particularly those specializing in pharmaceutical intermediates, is critical for ongoing research.

The synthesis of Carazolol involves multi-step organic chemistry processes, requiring careful control over reaction conditions and purification techniques. The product is often synthesized and supplied by chemical companies that focus on fine chemicals and pharmaceutical building blocks. When sourcing Carazolol, researchers should consult supplier specifications, which typically include details on purity assays (e.g., HPLC), melting point ranges, and potential impurities. These details are vital for validating the suitability of the compound for specific research protocols.

The pharmaceutical significance of Carazolol extends to its potential use as a reference standard in analytical chemistry for the detection and quantification of the compound in biological samples or environmental matrices. Its presence has been noted in wastewater effluent, prompting further research into its environmental fate and impact. For scientists working with beta-adrenergic pathways, understanding the chemical profile and sourcing options for Carazolol is a prerequisite for successful investigations.

In conclusion, Carazolol (CAS 57775-29-8) is a compound of substantial pharmaceutical interest due to its well-defined chemical structure and its potent beta-adrenergic receptor antagonist activity. Detailed knowledge of its properties and reliable sourcing from experienced chemical suppliers are essential for researchers aiming to leverage this compound in their work.